THC and CBD Suppressed a Key Inflammatory Immune Response Linked to Autoimmune Diseases | Research

The takeaway

Both THC and CBD suppressed the Th17 inflammatory immune response associated with autoimmune diseases like multiple sclerosis, reducing the pathogenic cytokine IL-17 while boosting the anti-inflammatory cytokine IL-10.

Read this if you have an autoimmune condition and are interested in how cannabinoids affect the immune system.

Cannabinoids suppressed pathogenic IL-17 while boosting anti-inflammatory IL-10

What the researchers found

Researchers studied immune cells that cause experimental autoimmune encephalitis (a model of multiple sclerosis) in mice. When these pathogenic T cells were reactivated, they produced large amounts of IL-17, a cytokine that drives autoimmune inflammation.

Both THC and CBD dose-dependently suppressed IL-17 production and secretion at concentrations of 0.1-5 micromolar. They also reduced IL-6, a key factor in Th17 cell development. CBD additionally increased IL-10, an anti-inflammatory cytokine. Neither cannabinoid affected TNF-alpha or IFN-gamma levels, showing specificity. The effects did not involve CB1, CB2, PPAR-gamma, 5-HT1A, or TRPV1 receptors, indicating a novel mechanism.

Why it matters

Th17 cells are major drivers of autoimmune diseases including multiple sclerosis, rheumatoid arthritis, and psoriasis. A treatment that specifically suppresses the Th17 response while boosting anti-inflammatory IL-10 would be highly valuable, and cannabinoids appear to do exactly this.

The numbers in context

THC and CBD: dose-dependent suppression at 0.1-5 micromolar. Suppressed: IL-17, IL-6. No effect on: TNF-alpha, IFN-gamma. CBD additionally increased IL-10. Receptor-independent: not through CB1, CB2, PPAR-gamma, 5-HT1A, or TRPV1.

How the study worked

In vitro study using MOG35-55-specific encephalitogenic T cells reactivated with spleen-derived antigen presenting cells. THC and CBD tested at 0.1-5 micromolar. Cytokine measurements: IL-17, IL-6, IL-10, TNF-alpha, IFN-gamma. Receptor involvement assessed with selective antagonists.

What this study cannot tell us

In vitro study with immune cells in a dish, not in living organisms. The concentrations used may not be achievable in the human body. The receptor-independent mechanism was identified by exclusion (blocking known receptors), but the actual target was not identified. Results from autoimmune encephalitis T cells may not generalize to all autoimmune conditions.

How to read the evidence

Well-controlled in vitro study with dose-response data; moderate preclinical evidence for a specific immunomodulatory effect.

When this study was published

Published in 2013. The Th17-suppressing properties of cannabinoids continue to be explored for autoimmune applications.

The bigger picture

This study reveals that cannabinoids have a highly specific immunomodulatory profile: they suppress the autoimmune Th17 pathway while leaving other immune responses intact and boosting anti-inflammatory responses. This specificity is unusual and therapeutically attractive.

Questions still open

Through what molecular target do cannabinoids suppress Th17 responses? Would these effects translate to clinical improvement in MS patients? Could cannabinoids complement existing immunomodulatory treatments? Is the CBD-specific IL-10 increase therapeutically meaningful?

Common questions

Could cannabis help treat autoimmune diseases?

This laboratory study shows that both THC and CBD can suppress the specific type of immune response (Th17) that drives autoimmune diseases like multiple sclerosis. While this is promising, it was conducted with cells in a dish, not in patients. The concentrations needed and whether these effects occur in the human body remain to be determined.

Is CBD or THC better for inflammation?

Both suppressed the Th17 inflammatory response similarly. However, CBD had an additional benefit: it increased IL-10, an anti-inflammatory cytokine. This dual action (suppressing pathogenic inflammation while boosting anti-inflammatory responses) may make CBD particularly attractive for autoimmune conditions, though clinical evidence is still needed.

Read the original research

Cannabinoids decrease the th17 inflammatory autoimmune phenotype.

Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 8(5), 1265-76

View on PubMed ↗Publisher’s paper ↗

Citation

Kozela, Ewa; Juknat, Ana; Kaushansky, Nathali; Rimmerman, Neta; Ben-Nun, Avraham; Vogel, Zvi. (2013). Cannabinoids decrease the th17 inflammatory autoimmune phenotype.. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 8(5), 1265-76. https://doi.org/10.1007/s11481-013-9493-1